MedTrace Logo

Opioid Modulation and Neural Reward Activation in Healthy Adults

NCT04854551 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-11-28

Study results available
· View outcomes & findings →

Summary

This is a double blind study of the effects of opioid antagonism on the brain's reward response. The investigators will recruit participants to undergo two scans, one on active medication and one on placebo. During the scan, the investigators will assess reward.

Conditions

  • Alcohol Drinking
  • Opioid Use, Unspecified

Interventions

DRUG

Naltrexone

Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.

OTHER

Placebo

Placebo will be used to control for expectancy effects

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Joshua Gowin, PhD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2022-04-18
Completion
2022-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04854551 on ClinicalTrials.gov